CMCatherine E. Munro

Catherine E. Munro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine E. Munro has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer R. Gatchel

    Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

    3 shared publications
  • Rebecca E. Amariglio

    Brigham and Women's Hospital

    3 shared publications
  • Yakeel T. Quiroz

    Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

    3 shared publications
  • Bernard Hanseeuw

    Institute of Neuroscience, Université Catholique de Louvain/Cliniques Universitaires Saint-Luc, Brussels, Belgium

    2 shared publications
  • Deborah Blacker

    Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

    2 shared publications
  • Dorene M. Rentz

    Department of Neurology, Brigham and Women's Hospital

    2 shared publications

Latest Publications

  • Open Access

    Neuropsychiatric symptoms across the revised Alzheimer's disease clinical staging framework: A review of current evidence and implications

    by Krushnaa Sankhe, Daniella Vellone, Dylan X. Guan, Byron Creese, Zahinoor Ismail, Sanjeev Kumar, Krista L. Lanctôt, Moyra E. Mortby, Fabricio Ferreira de Oliveira, Lindsey Sinclair, et al.

    The field of Alzheimer's disease (AD) research has seen major advances in understanding manifestations of AD‐related neuropsychiatric symptoms (NPS), including recent addition of NPS to the 2024 National Institute of Aging–Alzheimer's Association (NIA‐AA) clinical staging framework. This focused review highlights key publications (49 in 2024; 28 in 2025) indexed in MEDLINE examining AD‐related NPS, in alignment with the Scale for the Assessment of Narrative Review Articles guidelines. Data were thematically organized across NIA‐AA clinical stages, with emphasis on measurement, diagnosis, and biomarker‐cognition correlates of AD‐related NPS. Together, these findings can inform future research and clinical practice through enhanced understanding of AD‐related NPS and their relationships with pathology and clinical outcomes. Finally, three key priorities were identified for future research: (1) incorporating sex/gender and ethnocultural diversity; (2) integrating NPS assessment with cognitive, fluid, and neuroimaging biomarkers; and (3) including perspectives of individuals with lived experience to support personalized NPS management.

  • Comparing the associations between performance-based, participant-reported, and study partner-reported instrumental activities of daily living tasks and cognition in cognitively unimpaired adults

    by Abigail T. LaCasse, Catherine E. Munro, Hannah Truitt, Madeline Yu, Claudia R. Aibel, Onyinye J. Udeogu, Rebecca E. Amariglio, Dorene M. Rentz, Gad A. Marshall, Mark A. Dubbelman

    Background: Assessing instrumental activities of daily living (IADLs) is an integral diagnostic process for cognitive decline due to Alzheimer's disease (AD). While there are questionnaire-based and performance-based IADL measures, there is no clear consensus on the best methodology for a preclinical population. Objective: We aimed to compare performance-based and questionnaire-based IADL measures and investigate whether IADL measures differently predict cognition. Methods: One hundred and sixty-one cognitively unimpaired participants (mean age=70.69 ± 6.33 years; 62% female) completed performance-based IADL measures (i.e., Harvard Automated Phone Task [APT]; Czaja Functional Assessment Battery [CFAB]), questionnaire-based IADL measures (i.e., Cognitive Function Index [CFI]; The Alzheimer's Disease Cooperative Study Activities of Daily Living-Prevention Instrument [ADCS ADL-PI], also completed by study partners), and cognitive assessments. Separate cross-sectional linear regressions were used to determine (1) whether IADL questionnaires predicted performance-based measures, (2) whether IADL assessments predicted cognition. Results: Greater impairment on participant self-reported questionnaires (CFI and ADCS ADL-PI) were associated with worse performance on the CFAB automated teller machine task (R 2 = 0.36, p = 0.010; R 2 = 0.44, p = 0.003). Worse performance on the APT primary care physician task and greater impairment on participant self-reported CFI were associated with worse executive functioning (R 2 = 0.13, p = 0.003; R 2 = 0.06, p = 0.035) and slower processing speed (R 2 = 0.15, p = 0.009; R 2 = 0.22, p < 0.001). Greater impairment on the participant self-reported CFI was the only assessment associated with worse memory scores (R 2 = 0.14, p = 0.005). Conclusions: Among cognitively unimpaired older adults, few questionnaire-based IADL questionnaires were associated with performance-based measures. There was variability within and across IADL assessments’ associations with cognition, suggesting that not all IADL assessments are interchangeable.


  • Baseline cortical amyloid-β levels are associated with subsequent study-partner-rated apathy in community-dwelling older adults

    by Catherine E. Munro, Jacqueline Beltran, Phebe Palmer, Michelle Farrell, Bernard Hanseeuw, Dorene M. Rentz, Rachel Buckley, Michael Properzi, Patrizia Vannini, Rebecca E. Amariglio, et al.

    Background: Apathy is a common neuropsychiatric symptom in Alzheimer's disease (AD) and has been linked to greater levels of AD biomarkers (amyloid-β, tau). However, it is unclear whether early patterns of amyloid deposition may impact development of apathy symptoms in the future. Objective: We sought to examine whether amyloid-β levels, both globally and in brain regions associated with motivation, could predict future apathy symptoms. Methods: Participants (n = 199, mean age = 79.9) were part of the Harvard Aging Brain Study, a longitudinal observational cohort of individuals without cognitive or psychiatric impairment at baseline. All underwent MRI and Pittsburgh Compound B (PiB)-PET for amyloid-β at baseline and completed questionnaires of self- and study-partner-rated apathy 7.8 ± 1 years later using the Apathy Evaluation Scale. Linear regression models assessed whether regional PiB levels predicted future apathy scores. Results: Higher baseline cortical PiB levels in a frontal, lateral parieto-temporal, and retrosplenial aggregate were associated with greater study-partner-rated apathy, but not self-rated apathy, and no specific regional associations were observed outside of the aggregate. Conclusions: These results provide insight into early neurobiological underpinnings of AD-related apathy. Additionally, these data may have clinical implications regarding the risk of developing apathy symptoms in amyloid-β-positive individuals as cognition declines.

  • Open Access

    Change in Depressive Symptoms and Longitudinal Regional Amyloid Accumulation in Unimpaired Older Adults

    by Catherine E. Munro, Michelle Farrell, Bernard Hanseeuw, Dorene M. Rentz, Rachel Buckley, Michael Properzi, Ziwen Yuan, Patrizia Vannini, Rebecca E. Amariglio, Yakeel T. Quiroz, et al.

    Importance: Depressive symptoms in older adults may be a harbinger of Alzheimer disease (AD), even in preclinical stages. It is unclear whether worsening depressive symptoms are manifestations of regional distributions of core AD pathology (amyloid) and whether cognitive changes affect this relationship.Objective: To evaluate whether increasing depressive symptoms are associated with amyloid accumulation in brain regions important for emotional regulation and whether those associations vary by cognitive performance.Design, Setting, and Participants: Participants from the Harvard Aging Brain Study, a longitudinal cohort study, underwent annual assessments of depressive symptoms and cognition alongside cortical amyloid positron emission tomography (PET) imaging at baseline and every 2 to 3 years thereafter (mean [SD] follow-up, 8.6 [2.2] years). Data collection was conducted from September 2010 to October 2022 in a convenience sample of community-dwelling older adults who were cognitively unimpaired with, at most, mild baseline depression. Data were analyzed from October 2022 to December 2023.Main Outcomes and Measures: Depression (Geriatric Depression Scale [GDS]–30-item), cognition (Preclinical Alzheimer Cognitive Composite–5 [PACC]), and a continuous measure of cerebral amyloid (Pittsburgh compound B [PiB] PET) examined in a priori–defined regions (medial orbitofrontal cortex [mOFC], lateral orbitofrontal cortex, middle frontal cortex [MFC], superior frontal cortex, anterior cingulate cortex, isthmus cingulate cortex [IC], posterior cingulate cortex, and amygdala). Associations between longitudinal GDS scores, regional amyloid slopes, and PACC slopes were assessed using linear mixed-effects models.Results: In this sample of 154 individuals (94 [61%] female; mean [SD] age, 72.6 [6.4] years; mean (SD) education, 15.9 [3.1] years), increasing PiB slopes in the bilateral mOFC, IC, and MFC were associated with increasing GDS scores (mOFC: β = 11.07 [95% CI, 5.26-16.87]; t = 3.74 [SE, 2.96]; P = .004; IC: β = 12.83 [95% CI, 5.68-19.98]; t = 3.51 [SE, 3.65]; P = .004; MFC: β = 9.22 [95% CI, 2.25-16.20]; t = 2.59 [SE, 3.56]; P = .03). Even with PACC slope as an additional covariate, associations remained significant in these regions.Conclusions and Relevance: In this cohort study of cognitively unimpaired older adults with, at most, mild baseline depressive symptoms, greater depressive symptoms over time were associated with amyloid accumulation in regions associated with emotional control. Furthermore, these associations persisted in most regions independent of cognitive changes. These results shed light on the neurobiology of depressive symptoms in older individuals and underscore the importance of monitoring for elevated mood symptoms early in AD.


  • Open Access

    Depressive symptoms in relation to markers of neurodegeneration, cerebrovascular injury and Alzheimer’s Disease (AD) in community‐dwelling older adults: a plasma and multimodal neuroimaging study

    by Jennifer Gatchel, Kayden J. Mimmack, Yakeel T. Quiroz, Catherine E Munro, Jessa Burling, Keith A. Johnson, Reisa A. Sperling, Deborah Blacker, Grace Ma, Patrizia Vannini, et al.

    Background: Depressive symptoms are common with aging and Alzheimer’s Disease (AD). Both neurodegenerative and cerebrovascular diseases have been postulated as underlying mechanisms, but it’s unclear if they contribute to depressive symptom pathogenesis in preclinical stages of AD. Probing these mechanisms using both central (neuroimaging) and peripheral (plasma) biomarkers is critical to gain insight into the neurobiology of depression and provide opportunities for clinical translation.Method: Longitudinal data were analyzed from 350 Harvard Aging Brain Study participants, an observational cohort study of older adults who are cognitively unimpaired and have no/minimal depressive symptoms at baseline. Depressive symptoms were assessed annually with the 30‐item Geriatric Depression Scale (GDS) (average follow up = 7.2+/‐3.4yrs). At baseline, all participants underwent blood sampling for a plasma marker of general neurodegeneration, neurofilament light (NfL) and 11 cerebrovascular markers in plasma. Participants also underwent baseline amyloid (PiB) PET‐ wherein a cortical amyloid composite was derived‐ and baseline and subsequent MRI scans every three years‐ to derive slopes of regional cortical thickness and global white matter hyperintensities (WMH). Linear mixed effects models examined relationships between longitudinal GDS scores and predictors: (NfL or cerebrovascular markers)*time, and covariates: age, sex, education. Secondary model examined plasma markers and amyloid as interactive predictors of GDS, and repeated analyses using predictors: regional cortical thickness (neurodegeneration) or global WMH (cerebrovascular injury) slopes.Result: Higher baseline levels of NfL and of ICAM1, a marker of cerebrovascular injury, predicted increasing GDS scores over time (NfL: β = 0.03+/‐0.01, t = 2.7, p = 0.007; ICAM1: β = 0.02+/‐0.01, t = 2.2, p = 0.03). Each also interacted with amyloid in predicting GDS scores: (NfL X PiB: β = ‐0.03+/‐0.01, t = ‐2.42, p = 0.02; ICAM1 X PiB: β = 0.023+/‐0.01, t = 2.44, p = 0.02). Regarding neuroimaging correlates, medialorbitofrontal cortical thickness slope (β = ‐0.03+/‐0.01, t = ‐2.94, p = 0.004), but not global WMH slope, predicted increasing GDS over time. None of the other cerebrovascular markers interacted with amyloid in predicting GDS.Conclusion: Findings suggest that cerebrovascular injury, and peripheral and central biomarkers of regional neurodegeneration, alone and in synergy with amyloid burden, are associated with depressive symptoms in cognitively unimpaired older adults. Future studies incorporating additional measures of peripheral and central neurodegeneration, tauopathy, and cerebrovascular injury are needed to guide AD prevention efforts targeting depressive symptoms.

  • Open Access

    Recent contributions to the field of subjective cognitive decline in aging: A literature review

    by Catherine E. Munro, Rory Boyle, Xi Chen, Gillian Coughlan, Christopher Gonzalez, Roos J. Jutten, Jairo Martinez, Irina Orlovsky, Talia Robinson, Emma Weizenbaum, et al.

    Subjective cognitive decline (SCD) is defined as self‐experienced, persistent concerns of decline in cognitive capacity in the context of normal performance on objective cognitive measures. Although SCD was initially thought to represent the “worried well,” these concerns can be linked to subtle brain changes prior to changes in objective cognitive performance and, therefore, in some individuals, SCD may represent the early stages of an underlying neurodegenerative disease process (e.g., Alzheimer's disease). The field of SCD research has expanded rapidly over the years, and this review aims to provide an update on new advances in, and contributions to, the field of SCD in key areas and themes identified by researchers in this field as particularly important and impactful. First, we highlight recent studies examining sociodemographic and genetic risk factors for SCD, including explorations of SCD across racial and ethnic minoritized groups, and examinations of sex and gender considerations. Next, we review new findings on relationships between SCD and in vivo markers of pathophysiology, utilizing neuroimaging and biofluid data, as well as associations between SCD and objective cognitive tests and neuropsychiatric measures. Finally, we summarize recent work on interventions for SCD and areas of future growth in the field of SCD.